Arcion Therapeutics, a Baltimore-based clinical stage biotechnology company, received notice of allowance for a U.S. patent for its high-strength gel formulation of topical lidocaine, called ARC-2022, for pain associated with post-herpetic neuralgia and shingles, according to a company news release.
ARC-2022 contains lidocaine in a 40 percent concentration in a clear, water-based gel that can be applied directly to painful skin areas of the body. The treatment showed effectiveness in a single-dose phase 1 pharmacokinetic study in adult patients with post-herpetic neuralgia.
Related Articles on Pain Management:
5 Ways to Safeguard Against Opioid Abuse and Diversion From Robert Saenz, CEO of Tulsa Pain Consultants
Epidural Steroid Injections Increase Blood Glucose Levels in Patients With Diabetes
NeurogesX Appoints Ronald Martell President and Chief Executive Officer
ARC-2022 contains lidocaine in a 40 percent concentration in a clear, water-based gel that can be applied directly to painful skin areas of the body. The treatment showed effectiveness in a single-dose phase 1 pharmacokinetic study in adult patients with post-herpetic neuralgia.
Related Articles on Pain Management:
5 Ways to Safeguard Against Opioid Abuse and Diversion From Robert Saenz, CEO of Tulsa Pain Consultants
Epidural Steroid Injections Increase Blood Glucose Levels in Patients With Diabetes
NeurogesX Appoints Ronald Martell President and Chief Executive Officer